Heart Failure
Conditions
Interventions
Experimental group (Yi Qi Nuan Yang formula + basic treatment):On the basis of common basic treatment (evidence-based drug therapy, including diuresis, vasodilation, improving cardiac function, and re
Control group (basic treatment):Only common basic treatment (drug therapy guided by guidelines, including diuretics, vasodilation, improvement of cardiac function, and regulation of neuroendocrine sys
Sponsors
Taicang City Chinese Medicine Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1.Aged 18–85 years. 2.Diagnosed with acute heart failure, including acute decompensation of chronic heart failure, and requiring hospitalization for the current episode of decompensated heart failure. 3.Meeting the Traditional Chinese Medicine syndrome criteria for either qi deficiency or yang deficiency, together with the diagnostic criteria for dampness syndrome. 4.Able to take the study Chinese medicine orally during hospitalization and comply with all in-hospital assessments and sample collection. 5.Having provided written informed consent and being willing and able to complete the 90-day post-discharge follow-up.
Exclusion criteria
Exclusion criteria: 1. Subjects with hemodynamic instability or requiring advanced life support. 2. Subjects with severe infections or sepsis. 3. Subjects with end-stage renal disease, on dialysis, or expected to require dialysis during hospitalization. 4. Subjects with evident hepatic failure or deemed unsuitable for Chinese herbal medicine by the investigator. 5. Subjects with clear contraindications to warming and yang-restoring therapies, such as real heat syndrome or yin deficiency with hyperactivity of fire. 6. Subjects with other primary diseases causing dyspnea or edema, such as pulmonary embolism or severe exacerbation of COPD. 7. Subjects who are pregnant, breastfeeding, or planning to become pregnant. 8. Subjects with allergies to components of the study medication. 9. Subjects with poor adherence or unfeasible follow-up. 10. Subjects currently participating in other interventional clinical trials that may affect the assessment of the primary outcome.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 90-day heart failure readmission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Dampness Load Score;Serum sST2;Galectin-3;NT-proBNP;NYHA cardiac function classification; | — |
Countries
China
Contacts
Public ContactFan Lihua
Taicang City Chinese Medicine Hospital
Outcome results
None listed